STEVENSON, Wash., Dec. 21, 2011 (GLOBE NEWSWIRE) -- Total Nutraceutical Solutions, Inc. (TNS) (OTCBB:TNUS) announced today that it has received shareholder approval at its Annual Shareholders Meeting to amend the Company's Articles of Incorporation to change its name to Entia Biosciences, Inc. (Entia). Other matters approved by shareholders include the reelection of the Company's current board of directors, the formation of a new subsidiary, a 1:10 reverse split of the Company's common stock, and the engagement of Peterson Sullivan LLC as the Company's auditors for 2012.
The name change to Entia is part of an overall strategy that expands the Company's focus into food sciences biotechnology (nutrigenomics) and the development of branded and private label therapeutic dietary supplements and other solutions for large institutional customers. The newly formed subsidiary, which will be called Total Nutraceutical Solutions, Inc., will focus exclusively on consumer oriented products that utilize Entia's proprietary technology, such as the popular Groh™ and SANO™ nutraceutical brands.
On December 5th, the Company changed its stock symbol to "ERGO" with the intention of increasing investor awareness of its new corporate identity, institutional focus, and ErgoD2™ branded formulations. ErgoD2™ is an optimized blend of the two powerful antioxidants Ergothioneine and Ergocalciferol (vitamin D2), which is now being studied by Massachusetts General Hospital as a potential dietary therapy or palliative therapy for Parkinson's disease patients. Entia intends to announce additional collaborative research studies and clinical trials in the coming months that will address other potential applications for the Company's proprietary food-based technology and products.
"How we present ourselves to the market is important for both our customers and investors," stated Marvin S. Hausman MD, CEO of TNS. "We are excited to be starting the New Year as Entia Biosciences and look forward to continued progress with our Ergo-based products in the months ahead. There is an evolving revolution in the field of nutrition and Entia intends to use its breakthrough food-based antioxidant technology to achieve the ambitious goal of optimizing a person's health and ability to live longer through nutritional intervention." In December, the Company announced the issuance of its first Ergothioneine-related patent for use in food and beverages and has additional patent applications pending in North America and the European Union.
The Company is currently in the process of filing the name change, reverse stock split, and new subsidiary with the appropriate regulatory agencies, with a targeted effective date of January 6th, 2012.
About Entia Biosciences, Inc. and Total Nutraceutical Solutions, Inc.
Entia Biosciences is an emerging leader in whole food biotechnology that identifies, scientifically validates, and commercializes solutions that address multi-billion dollar markets for organic health, beauty and agriculture. The Company's growing portfolio of intellectual property includes extraction, enhancement, and uses for some of the most powerful antioxidants and bionutrients occurring in nature. For more information, please visit our web sites at www.entiabio.com and www.totalnutraceuticals.com.
The Total Nutraceutical Solutions, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8060
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Total Nutraceutical Solutions (TNS), Inc. with the Securities and Exchange Commission. Further information on risks faced by TNS are detailed in the Form 10-K for the year ended December 31, 2010 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at www.sec.gov/" target="_top" rel="nofollow">http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. TNS does not undertake any obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.